New study aims to prevent dangerous ketosis in type 1 diabetes patients with kidney disease
NCT ID NCT07325201
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how to safely use a type of diabetes drug (SGLT1&2 inhibitor) in people with type 1 diabetes and mild to moderate chronic kidney disease. The goal is to find out what increases the risk of a serious condition called diabetic ketoacidosis (DKA). About 80 adults will wear continuous glucose and ketone monitors and take the study drug for nine months. The results will help create better reports to warn patients and doctors about ketosis risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
International Diabetes Center
Minneapolis, Minnesota, 55416, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk